



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/137632/>

Version: Accepted Version

---

**Article:**

Tanaka, M, Suwatthanarak, T, Arakaki, A et al. (2018) Enhanced Tubulation of Liposome Containing Cardiolipin by MamY Protein from Magnetotactic Bacteria. *Biotechnology Journal*, 13 (12). ISSN: 1860-6768

<https://doi.org/10.1002/biot.201800087>

---

© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. This is the pre-peer reviewed version of the following article: Tanaka, M, Suwatthanarak, T, Arakaki, A et al. (5 more authors) (2018) Enhanced Tubulation of Liposome Containing Cardiolipin by MamY Protein from Magnetotactic Bacteria. *Biotechnology Journal*, which has been published in final form at <https://doi.org/10.1002/biot.201800087>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



## Enhanced tubulation of liposome containing cardiolipin by MamY protein from magnetotactic bacteria

Journal:	<i>Biotechnology Journal</i>
Manuscript ID	biot.201800087.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Tanaka, Masayoshi; Tokyo Institute of Technology - Ookayama Campus, Department of Chemical Science and Engineering Suwatthanarak, Thanawat; Tokyo Institute of Technology - Ookayama Campus, Department of Chemical Science and Engineering Arakaki, Atsushi ; Tokyo University of Agriculture and Technology, Division of Biotechnology and Life Science Johnson, Benjamin; University of Leeds, School of Physics and Astronomy Evans, Stephen; University of Leeds, School of Physics and Astronomy Okochi, Mina; Tokyo Institute of Technology, Staniland, Sarah; University of Sheffield, Chemistry department Matsunaga, Tadashi; Tokyo University of Agriculture and Technology; Waseda University, Faculty of Science and Engineering
Primary Keywords:	Nanobiotechnology, Biomaterials
Secondary Keywords:	Bionanotechnology, Microbiology
Additional Keywords:	Magnetotactic bacteria, Lipid tube, Cardiolipin

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 Research Article

5  
6 Special issue

7  
8 AFOB XI: Biomimetic and Bioinspired Biotechnology-Bentley & Gotoh & Martin

9  
10  
11 **Enhanced tubulation of liposome containing cardiolipin by MamY protein from**  
12 **magnetotactic bacteria**

13  
14  
15  
16  
17 Masayoshi Tanaka<sup>1\*</sup>, Thanawat Suwatthanasarak<sup>1</sup>, Atsushi Arakaki<sup>2</sup>, Benjamin R. G.  
18 Johnson<sup>3</sup>, Stephen D. Evans<sup>3</sup>, Mina Okochi<sup>1</sup>, Sarah Staniland<sup>4</sup>, and Tadashi Matsunaga<sup>2,5\*</sup>

19  
20  
21  
22  
23 <sup>1</sup>Department of Chemical Science and Engineering, Tokyo Institute of Technology, Tokyo,  
24 Japan, <sup>2</sup>Division of Biotechnology and Life Science, Institute of Engineering, Tokyo  
25 University of Agriculture and Technology, Tokyo, Japan, <sup>3</sup>School of Physics and Astronomy,  
26 University of Leeds, Leeds, UK, <sup>4</sup>Department of Chemistry, University of Sheffield,  
27 Sheffield, UK, <sup>5</sup>Faculty of Science and Engineering, Waseda University, Tokyo, Japan

28  
29  
30 **Correspondence:**

31  
32 **Tadashi Matsunaga**, Division of Biotechnology and Life Science, Institute of Engineering,  
33 Tokyo university of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo 184-  
34 8588, Japan. **E-mail:** tmatsuna@cc.tuat.ac.jp

35  
36  
37  
38 **Masayoshi Tanaka**, Department of Chemical Science and Engineering, Tokyo Institute of  
39 Technology 2-12-1, O-okayama, Meguro-ku, Tokyo 152-8552, Japan. **E-mail:**  
40 m\_tanaka@chemeng.titech.ac.jp

41  
42  
43  
44 **Keywords:** Cardiolipin, Magnetosome, Magnetotactic bacteria, Membrane tubulation,  
45 Peptide array

46  
47  
48 **Abbreviations:** *M. magneticum* AMB-1, *Magnetospirillum magneticum* AMB-1; **BAR**,  
49 Bin/amphiphysin/Rvs; **TEM**, Transmission electron microscopy; **CL**, Cardiolipin; **ML**,  
50 Liposome made of magnetosome membrane extracted lipids

**Abstract**

Lipid tubules are of particular interest for many potential applications in nanotechnology. Among various lipid tubule fabrication techniques, the morphological regulation of membrane structure by proteins mimicking biological processes may provide the chances to form lipid tubes with highly-tuned structures. Magnetotactic bacteria synthesize magnetosomes (a unique prokaryotic organelle comprising a magnetite crystal within a lipid envelope). MamY protein has previously been identified as the magnetosome protein responsible for magnetosome vesicle formation and stabilization. Furthermore, MamY has been shown *in vitro* liposome tubulation activity. In this study, the interaction of MamY and phospholipids was investigated by using a lipids-immobilized membrane strip and a peptide array. Here, the binding of MamY to the anionic phospholipid, cardiolipin, was found and enhanced liposome tubulation efficiency. We propose the interaction is responsible for recruiting and locating cardiolipin to elongate liposome *in vitro*. We also suggest a similar mechanism for the invagination site in magnetosomes vesicle formation, where the lipid itself contributes further to increasing the curvature. These findings are highly important to develop an effective biomimetic synthesis technique of lipid tubules and to elucidate the unique prokaryotic organelle formation in magnetotactic bacteria.

## 1 Introduction

The fabrication of self-assembled lipid nanotubules *in vitro* is an exciting research topic because its applications are diverse. Using unique properties including structural flexibilities (e.g. diameter, length and wall thickness), ease of surface functionalization and biocompatibility, the materials can be used as nanoreactors for functional material synthesis<sup>[1-4]</sup>, templating the fabrication of biocompatible functional one-dimensional materials<sup>[5-7]</sup> and drug carriers<sup>[8-10]</sup>. Because of these wide areas of interest, extensive research efforts have been devoted towards finding a means of creating such unique membrane structures *in vitro* and for elucidating the mechanisms of lipid tubule formation.

Various fabrication techniques of lipid tubules have been developed since the first report in 1984<sup>[11]</sup> by self-assembly of diacylene phospholipids. The techniques are generally categorized in two groups: the design of lipid molecules with appropriate structure and compositions for their self-assembling<sup>[12,13]</sup>, and the morphological regulation by external stimuli such as pulling lipid vesicles with a pipette<sup>[14]</sup>, electric fields<sup>[15]</sup>, light irradiation<sup>[16]</sup>, interaction with cationic particles<sup>[17]</sup> and proteins<sup>[18-20]</sup>. Among these approaches, the use of proteins mimicking biological systems is potential candidate for a range of lipid tubule formation with both highly-tuned and of more-complicated structures because of the variety of precise protein-regulated membranous structures observed in biology (e.g. endoplasmic reticulum, Golgi network, inner mitochondrial membrane, etc.)<sup>[21-23]</sup>.

The protein-lipid interaction is an important part of regulating the membranous structure for cellular activity expressions. In eukaryotic cells, the Pleckstrin homology domain in phospholipase C- $\delta$ 1 produces a pulling force of membranous structure to form a membrane compartment through the interaction with phosphorylated phosphatidylinositols<sup>[24]</sup>. The proteins possessing Bin/amphiphysin/Rvs (BAR) domain

1  
2  
3  
4 also bound to phosphatidylinositols and the diverse BAR protein family including I-BAR  
5 and F-BAR have an important role for membrane invagination processes<sup>[23,25-28]</sup>. In  
6  
7 prokaryotic cell, while the dynamic organization behaviors of lipid- protein localization for  
8  
9 cell division have been investigated<sup>[29-33]</sup>, research of protein-lipid interaction for  
10  
11 prokaryotic organelle formation is lacking thus far.  
12

13  
14 Magnetotactic bacteria are fascinating to many scientists due to the presence of  
15  
16 prokaryotic membranous organelles, called magnetosomes, that comprise a crystalline  
17  
18 magnetite core within a lipid envelope, or magnetosome membrane<sup>[34,35]</sup>. Previous  
19  
20 molecular studies have reported that the complicated biomineralisation process is  
21  
22 regulated by a unique set of proteins within the cells<sup>[36-40]</sup>. Briefly, magnetosome  
23  
24 membranes are formed from cytoplasmic membrane through an invagination process<sup>[36,41]</sup>  
25  
26 and the vesicles are then aligned along the actin-like filamentous protein<sup>[41-43]</sup>. Magnetite  
27  
28 crystals are formed within magnetosome vesicles in a highly controlled manner regulated  
29  
30 by a suite of magnetosome biomineralisation proteins <sup>[44-46]</sup>. During the organelle  
31  
32 formation process, the interaction between specific membrane protein and lipids in the  
33  
34 membrane might prove to be pivotal. Our research group has identified a magnetosome  
35  
36 membrane protein, MamY, which has been isolated from magnetosome containing small  
37  
38 magnetite crystal (presumably in immature stage)<sup>[47]</sup>. The *mamY* gene deletion mutant  
39  
40 showed the expansion of magnetosome vesicle sizes and the increase of small magnetite  
41  
42 crystals, showing MamY's role in the vesicle invagination step. Furthermore, MamY can  
43  
44 directly bind to biological membrane vesicles (liposome) and cause the deformation from  
45  
46 sphere to tubule *in vitro*<sup>[47]</sup>. Therefore, while MamY is hypothesized to be related to the  
47  
48 invagination of the magnetosome vesicle, the molecular mechanisms including protein-  
49  
50 membrane binding interactions are still unclear.  
51

52 Here, we investigated the interaction of the MamY protein and a range of lipids by  
53  
54 (1) binding assay of MamY protein to various phospholipids, (2) evaluation of liposome  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 deformation efficiency by MamY protein in the presence of the best binding candidate  
5 lipid (cardiolipin (CL)), and (3) binding assay of a series of peptides derived from amino  
6 acid sequence of MamY protein to CL. This is the first report showing the direct interaction  
7 between a magnetosome membrane protein and specific lipids. The results in this study  
8 not only provide the preliminary understanding the presence of a unique protein-lipid  
9 interaction is responsible for magnetosome formation in magnetotactic bacteria, but also  
10 suggests of how prokaryotic protein could be used to biomimetically synthesize lipid  
11 tubule *in vitro*.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## 22 **2 Materials and methods**

### 23 **2.1 Materials**

24 DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, 18:1) and CL (Cardiolipin, 18:1) were  
25 purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Membrane Lipid Strips were  
26 obtained from Echelon Bioscience, Inc. (Salt Lake, UT, USA). All other reagents were of the  
27 highest commercial grade available. *M. magneticum* AMB-1 (ATCC700264) was cultured  
28 anaerobically in magnetic spirillum growth medium (MSGM) in a 8-L fermentor as  
29 described previously<sup>[45,48]</sup>.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **2.2 Lipid-strip binding assay**

41 The *mamY* gene was amplified from *M. magneticum* AMB-1 as previously described<sup>[47]</sup>. The  
42 gene of AmphiphysinBAR protein (human Amphiphysin aa1-239) was cloned into  
43 pGEX6p3. Recombinant proteins (MamY and AmphiphysinBAR) were expressed as fusion  
44 proteins with glutathione S-transferase (GST) using plasmid vector of pGEX6p-1 and  
45 pGEX6p-3, respectively (GE Healthcare Life Sciences, Chicago, Illinois, USA) in *E. coli* BL21.  
46 These recombinant proteins were purified with glutathione-sepharose, size-exclusion, and  
47 ion-exchange chromatography. Purity (>95%) of these proteins was verified by SDS-PAGE.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 For the protein-lipid binding assay, various lipids dotted on strips (Echelon Bioscience  
5 Inc., Salt Lake, UT, USA) were blocked with PBS-T buffer (pH 7.4) (137 mM NaCl, 2.7 mM  
6 KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.47 mM KH<sub>2</sub>PO<sub>4</sub>, 0.1% (v/v) Tween-20) supplemented with 3%  
7 BSA for 1h with gentle agitation 25°C. After discarding the blocking solution, protein  
8 solutions (0.5 µg ml<sup>-1</sup> proteins in PBS) were incubated with gentle agitation for 1h at room  
9 temperature. The strips were then washed with PBS-T buffer three times with gentle  
10 agitation for 5 min each. The washed strips were incubated with mouse anti-GST antibody  
11 (GE Healthcare Life Sciences, Chicago, Illinois, USA) for 1 h and washed three times. Anti-  
12 mouse IgG-HRP (Horseradish peroxidase) (Thermo Fisher Scientific, Waltham,  
13 Massachusetts, USA) was used as a secondary antibody and washed three times. The  
14 immunoreactivity was visualized with the ECL detection system (GE Healthcare Life  
15 Sciences, Chicago, Illinois, USA).

### 2.3 Synthesis of peptide arrays

30  
31 Peptide library of 15-amino-acid peptides was constructed by overlapping 2 amino acids  
32 along the sequence of MamY protein and synthesized on cellulose membranes (grade 542;  
33 Whatman, Maidstone, UK) activated with β-alanine as N-terminus by peptide auto-spotter  
34 (MultiPep Rsi, Intavis AG, Köln, Germany) as shown in previous works [49,50]. It should be  
35 noted that the peptide array comprising the 15-mer peptides could reveal the importance  
36 of native secondary protein structure<sup>[63]</sup>. For the addition of each amino acid, the synthesis  
37 cycle began with deprotecting Fmoc-protecting group with 20% piperidine in N,N-  
38 dimethylformamide (DMF) before washing the membrane with DMF and ethanol. Prior to  
39 amino acid coupling, Fmoc amino acids at 0.5 M were activated by 1.1 M  
40 Hydroxybenzotriazole and 1.1 M N,N-diisopropylcarbodiimide. After coupling, the  
41 remaining unreacted amino groups were blocked by 4% acetic anhydride in DMF and  
42 subsequently washed with DMF and ethanol. The synthesis was conducted according to  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 manufacturer's instructions with some modifications. After the final cycle, Fmoc and side-  
5 chain protecting groups were manually removed with 20% piperidine in DMF and mixture  
6 of Milli-Q water, triisopropyl silane and trifluoroacetic acid (2:3:95), respectively. Finally,  
7 the membrane was thoroughly washed with dichloromethane, DMF, ethanol and PBS.  
8  
9

#### 14 **2.4 Liposome tubulation assay**

15  
16 Cultured *M. magneticum* AMB-1 cells were resuspended in 10 mM HEPES buffer (pH 7.4)  
17 and disrupted twice by French press (2,000 kgf cm<sup>-3</sup>) on ice. After centrifugation,  
18 magnetosomes were collected magnetically by a cylindrical Nd-B magnet (15 mm in  
19 diameter, 10 mm in height). Total lipids from magnetosome membrane vesicle were  
20 extracted according to Bligh and Dyer extraction method<sup>[51]</sup>. A liposome tubulation assay  
21 was conducted as described previously<sup>[47,52]</sup> with minor modifications. Prior to making the  
22 liposome solution, glass vials were thoroughly washed with chloroform, methanol, MilliQ  
23 and chloroform. After mixing lipid components for liposome formation in chloroform, the  
24 solution was dried under argon gas purging and incubated in desiccator for more than 2h.  
25  
26 As no tubulation was found for small unilamellar vesicle by MamY protein in our  
27 preliminary investigation, giant unilamellar vesicle (GUV) was applied for the tubulation  
28 assay. To form GUV, 0.3 M sucrose solution was added in the glass vial containing  
29 thoroughly dried lipid cake and were incubated overnight at 37°C. Liposomes (1 mg ml<sup>-1</sup>  
30 lipid) were then mixed with MamY-GST (final conc.: 30 μM). After incubation for 30 min at  
31 37°C, the samples were spotted onto 150-mesh carbon-coated copper grids (Nisshin EM  
32 Co., Tokyo, Japan), stained with 1% (w/v) phosphotungstic acid, and analyzed using JEOL  
33 JEM1200EX (JEOL, Tokyo, Japan) operated at an accelerating voltage of 100 kV. To  
34 evaluate the tubulation activity of MamY-GST protein in this experimental condition, GST  
35 protein was also evaluated as negative control, and no tubulation was found.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2.5 Binding assay between liposome containing CL and peptide array

DOPC, CL and Texas red tagged DHPE (Thermo Fisher Scientific, Waltham, Massachusetts, USA) dissolved in chloroform were mixed with the ratio of 10:1:0.044 for CL-containing DOPC liposome or 10:0:0.04 for DOPC liposome. The mixture was dried under argon gas purging and kept in desiccator for more than 2 h. The obtained lipid cake was hydrated with PBS before 2-min sonication and then 30-s vortex. The lipid solution was extruded through 0.1  $\mu\text{m}$  membrane using an extruder (Avanti Polar Lipids, Inc., Alabama, USA).

The peptide array was blocked with 5% BSA in PBS for 30 min and triplicate washed with 0.05% Tween 20 in PBS for 3 min. The peptide array was soaked into the liposome solution diluted with PBS to 100  $\mu\text{g}/\text{ml}$  for 1 h and triplicate washed with PBS for 3 min. All steps in binding assay were performed at 25°C with gentle agitation. Fluorescence scanning and imaging were performed by biomolecular imager (Typhoon FLA 9500, GE Healthcare, Uppsala, Sweden) using 653 nm excitation wavelength, 669 nm emission light wavelength with LPR filter at 50  $\mu\text{m}$ -pixel size with 500 V. The fluorescence image was quantified by Image Quant software (GE Healthcare, Uppsala, Sweden).

Dissociation constants ( $K_d$ ) of candidate peptides with CL were determined by binding assay between liposomes and peptide array. The assay was tested at different liposome concentrations ranging from 0 to 150  $\mu\text{g}/\text{ml}$ . Fluorescence intensity from binding assay with CL-containing DOPC liposome was subtracted by that with DOPC liposome to specify the binding intensity for CL. Binding curves were drawn between blank-subtracted intensity and CL concentration for  $K_d$  determination. Langmuirian binding isotherm equation  $\{Y = B_{\text{max}} \times X / (K_d + X)\}$  was used, where Y was blank-subtracted intensity, X was concentration of CL, and  $B_{\text{max}}$  was the intensity at saturation. All  $K_d$  values were calculated from SigmaPlot 11.0 software (Systat Software Inc., California, USA).

1  
2  
3  
4 To confirm the binding between candidate peptide and CL, binding assay by  
5 surface plasmon resonance (SPR) system (Biacore X100 Plus Package, GE Healthcare,  
6 Uppsala, Sweden) was conducted. AAFGKLNSASRAALI or AAAA peptide dissolved in  
7 acetate pH 5.5 to 0.5 mg/ml was immobilized on CM5 sensor chip surface using amine  
8 coupling kit at 5  $\mu$ l/min for 18 min. The immobilized response was around 300 and 200  
9 RU for AAFGKLNSASRAALI and AAAA peptide, respectively. For binding analysis, the  
10 analyte, 10% CL-containing DOPC liposomes or DOPC liposomes diluted with HBS-EP  
11 buffer to 1 mg/ml, was applied at a flow rate of 10  $\mu$ l/min for 180 s followed by 600 s of  
12 dissociation time. After each binding analysis, the surface was regenerated by 10 mM  
13 glycine-HCl pH 2.0 at a flow rate of 10  $\mu$ l/min for 1 min.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **3 Results**

#### 27 **3.1 Binding assay between MamY protein and various phospholipids using** 28 **membrane lipid array** 29 30 31

32 To test whether MamY can bind to specific phospholipids, MamY-GST and a series  
33 of phospholipids were used to conduct a protein-lipid overlay binding assay. As shown in  
34 Fig. 1, unexpectedly, the unique binding properties of MamY protein to CL and 3-  
35 sulfogalactosylceramide (sulfatide) were clearly observed by chemiluminescence  
36 detection (Fig. 1A), while no binding to other phospholipids including the major lipid  
37 components (PE; phosphatidylethanolamine, PS; phosphatidylserine, and PC;  
38 phosphatidylcholin) in the magnetosome membrane of *M. magneticum* AMB-1<sup>[36]</sup> were  
39 found. On the other hand, BAR domain of human Amphiphysin (AmphiphysinBAR,  
40 control) bound to phosphatidylinositols [PtdIns(4)P, PtdIns(4,5)P<sub>2</sub>, and PtdIns(3,4,5)P<sub>3</sub>],  
41 sulfatide, phosphatidic acid, phosphatidylserine (PS), phosphatidylethanolamine (PE),  
42 phosphatidylglycerol (PG) and CL (Fig. 1B), while the negative control (GST) showed no  
43 binding ability to any lipids on the lipid array as also reported previously<sup>[53]</sup> (Fig. 1C).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Among a range of negatively charged lipids in the strip, only two negatively charged lipids  
5 (CL and sulfatide) showed binding to MamY protein. The observation suggested that  
6 (CL and sulfatide) showed binding to MamY protein. The observation suggested that  
7 although a negative charge is essential, the interaction is not derived simple from  
8 electrostatic interaction. The unique feature of protein binding specifically to CL and  
9 Sulfatide has previously been reported for  $\alpha$ -helices regions in some proteins<sup>[54,55]</sup>. While  
10 the binding mechanism is still unclear in these proteins, similar interaction may  
11 contribute to the binding here because the MamY protein is also predicted to be dominant  
12 by  $\alpha$ -helices regions<sup>[47]</sup>. Sulfatide is the major acidic glycosphingolipid in central and  
13 peripheral nerve myelin in mammals<sup>[56]</sup>. As the lipid group of glycosphingolipids including  
14 Sulfatide is generally synthesized only in eukaryotic cell with a few exceptions<sup>[57,58]</sup>, we  
15 focused on the interaction between MamY and CL in the following experiments.

### 3.2 Tubulation assay of liposome containing CL by MamY protein

30 MamY has been previously shown to have deformation function of liposomes from  
31 spherical to tubulated morphology<sup>[47]</sup>. As the interaction between MamY and CL was  
32 confirmed in this study, as the next step, it was investigated whether the interaction  
33 enhances the liposome tubulation *in vitro*. In the presence of MamY-GST protein, liposome  
34 tubulation was clearly observed, while liposomes were spherical morphologies in the  
35 absence of MamY (Fig. 2). In addition, as found in Table 1, the tubulation efficiency was  
36 increased according to the increase of CL concentration. When the liposome was made of  
37 pure magnetosome membrane lipids (ML), the tubulation efficiency was 3.3%. It should be  
38 noted that the GST tag has a negligible effect on the liposome tubulation activity of MamY  
39 (tubulation activity of MamY-GST (3.3%) was similar level to MamY without GST tag  
40 (approximately 4%)<sup>[47]</sup>). GST protein also showed no liposome tubulation activity. At 5%,  
41 10% and 20% of CL, a tubulation efficiency of approximately 20% was reached. This result  
42 demonstrated that MamY interacts with CL, and the interaction is associated with

liposome tubulation. The tubulation efficiency of liposome comprising magnetosome lipids supplemented with CL seems to be maximum at approximately 20%, and all MamY molecule seems to be used for the tubulation of liposome containing 5% or more CL.

### 3.3 Binding assay between MamY derived peptides and CL containing liposome using peptide array

To begin to understand the location of the CL binding region and mechanism of how MamY binds to CL, a 15-mer peptide library (188 peptides) constructed by overlapping 2 amino acids along the sequence of MamY protein (389 amino acids) was synthesized (Fig. 3A). A binding assay of this array to CL-containing DOPC liposome and DOPC liposome (control) was performed (Fig. 3). Some peptide spots showed higher intensity with CL-containing DOPC liposome than DOPC liposome (Fig. 3B). In addition, previously reported CL binding peptide<sup>[59]</sup>(shown as “C” peptide in Fig. 3B), KNKEKK, shows binding only for CL-containing DOPC liposome. In order to quantitatively evaluate the binding to CL, the fluorescence intensity profile of DOPC liposome was subtracted from CL containing DOPC liposome (Fig. 3C). Herein, 8 peptides having greater intensity than average (+ 2SD value were selected as CL binding peptides (Table 2)) and the intensity was remarkably higher than the control peptide. SPR experiment using a screened CL binding candidate peptide (AAFGKLN SASRAALI) and tetra-alanine peptide (negative control) was applied to confirm the results from binding assay. In this assay, each peptide was immobilized on a sensor chip surface, and subsequently the solution containing liposome was flowed to observe the bound mass proportion on the surface along time. From blank-subtracted SPR sensor-gram, the bound mass or response on AAFGKLN SASRAALI peptide-immobilized surface was larger when CL-containing DOPC liposome was flowed (Supplementary figure 1-A). From this data, strong binding activity of screened peptide to CL was clearly confirmed by comparison with only DOPC

1  
2  
3  
4 liposomes. In contrast, AAAA peptide-immobilized surface display insignificant difference  
5  
6 with the both types of liposome (Supplementary figure 1-B). In addition, a protein region  
7  
8 from aa280 to aa339 seems to be important for CL binding because 4 peptides were  
9  
10 collectively found. As the peptides had a wide range of isoelectric point (pI) from 4.53 to  
11  
12 11.54 and of the GRAVY (grand average of hydropathy) value from -1.91 to 0.67, various  
13  
14 types of interaction to CL in each peptide may occur.

15  
16 The dissociation constant ( $K_d$ ) of 8 candidate peptides (named p1-p8) to CL along  
17  
18 with control peptide were determined by binding assay with CL-containing DOPC  
19  
20 liposome and DOPC liposome using peptide array. By using the Langmuirian binding  
21  
22 isotherm equation (see materials and methods), each  $K_d$  value of candidate peptides to CL  
23  
24 was calculated (Table 2) (Supplementary figure 2). All candidate peptides except p2 have  
25  
26 stronger affinity to CL than control peptide (KNKEKK,  $K_d=9.49 \mu\text{M}$ ) in this experimental  
27  
28 condition. Among these peptides, p6 (RKFISTLTTAYFAGD) showed the strongest affinity  
29  
30 to CL ( $K_d=0.65 \mu\text{M}$ ). The pI (8.59), GRAVY (0.07) and net charge (+1) were relatively  
31  
32 neutral in this CL binding peptide candidates.

#### 33 34 35 36 **4 Discussion**

37  
38 In this study, the interaction between a prokaryotic membrane deformation  
39  
40 protein, MamY, and CL was found. From the binding assay between CL and peptide library  
41  
42 derived from MamY amino acid sequence, some peptides were suggested to play an  
43  
44 important role for the interaction. This is the first report showing the direct interaction  
45  
46 between magnetosome membrane protein and specific lipid. Furthermore, by the  
47  
48 supplementation of CL to liposome, the effective liposome tubulation condition was  
49  
50 developed.

51  
52 Binding of MamY protein to negatively charged CL was disclosed in this study. In  
53  
54 this experimental condition (pH=7.4), the protein (pI=5.38) seems to be a generally  
55  
56

1  
2  
3  
4 negatively charged molecule. This is interesting because the result suggests that the  
5  
6 interaction is not simply derived from electrostatic interaction as a whole protein  
7  
8 molecule. By evaluation of binding between peptide sequences derived from MamY and CL,  
9  
10 as all 8 peptides included positively charged amino acids (R or K) and hydrophobic amino  
11  
12 acids (e.g., V, I, L)(Table 2), both of the electrostatic and hydrophobic interaction seem to  
13  
14 be contributed for the binding to CL. A lipid bilayer is a dynamic environment with varying  
15  
16 properties ranging from nonpolar within the hydrocarbon chain to the polar headgroup-  
17  
18 solution interface. Therefore, selective binding may occur between various amino acids  
19  
20 within the screened peptides interacting with the CL molecule. In addition, it is reported  
21  
22 that some  $\alpha$ -helix repeat structure within the protein relate to the stable binding to other  
23  
24 biological membranes and its deformation<sup>[60,61]</sup>, the structural feature of MamY protein  
25  
26 comprising of repeat of  $\alpha$ -helix may also contribute to the stable binding to CL. In fact, all 8  
27  
28 candidate peptides were found in  $\alpha$ -helix regions of MamY protein predicted by  
29  
30 PSIPRED(<http://bioinf.cs.ucl.ac.uk/psipred/>)<sup>[62]</sup>(Supplementary figure 2). On the other  
31  
32 hand, since there is no report of 3D structure of MamY protein thus far, it is still unclear  
33  
34 whether these peptides interact at plural sites or at nearby sites in the protein structure.  
35  
36 Further study including protein structural analysis should be addressed to fully  
37  
38 understand the molecular mechanism of magnetosome vesicle regulation by MamY  
39  
40 protein.

41  
42 The supplementation of CL in liposome enhanced the tubulation efficiency by  
43  
44 MamY protein, but the mechanism of liposome tubulation is still unclear. CL is an anionic  
45  
46 tetraacylphospholipid which is almost exclusively confined to the innermitochondrial  
47  
48 membrane in eukaryotic cells, whereas in prokaryotes, it has been identified in the  
49  
50 cytoplasmic membrane. For example, CL-enriched membrane domains were reported in  
51  
52 bacterial cells, *E. coli*<sup>[29,30]</sup>, *Bacillus subtilis*<sup>[64]</sup> and *Pseudomonas putida*<sup>[65]</sup>. As a result of its  
53  
54 conical shape, CL employs lateral pressure on a membrane containing other  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 phospholipids, and results in membrane curvature formation. In fact, in *E. coli* cells, CL is  
5  
6 localized at the cell poles due to the membrane curvature<sup>[29,30]</sup>. As the size of magnetosome  
7  
8 vesicle is approximately 100 nm, the membrane seems to be one of the most highly-curved  
9  
10 membrane structure in magnetotactic bacteria. Therefore, MamY may play important role  
11  
12 for the recruitment of CL to magnetosomes in order to induce the formation of highly-  
13  
14 curved vesicle formation and/or stabilization of the structure. The hypothesis is also  
15  
16 supported by the bioinformatics analysis. Based on the protein domain analysis of MamY  
17  
18 by Pfam<sup>[47]</sup>, p4 and p7 are expected to have a similarity with caspase recruitment  
19  
20 domain<sup>[66]</sup>, involving in apoptotic signaling and requiring CL as a binding platform to  
21  
22 recruit apoptotic factors<sup>[67]</sup>. In addition, based on the proteomic and genomic studies in  
23  
24 magnetotactic bacteria, dozens of proteins including filamentous MamK protein and  
25  
26 functionally unclear proteins have been suggested to play important roles for  
27  
28 magnetosome formation<sup>[36,39,40,68,69]</sup>. In eukaryotic cells, as BAR protein regulates the  
29  
30 intracellular vesicle formation cooperated with filamentous actin protein and with various  
31  
32 other proteins<sup>[70]</sup>, MamY protein may also function to form the magnetosome vesicle  
33  
34 cooperatively with other magnetosome proteins. By the utilization of these proteins with  
35  
36 MamY, liposome tubulation efficiency may be further improve. As shown in other  
37  
38 literatures reported about liposome tubulation proteins<sup>[28,52,71–73]</sup>, further investigations  
39  
40 about MamY function in both *in vivo* and *in vitro*, including the dynamics analysis of each  
41  
42 lipid and protein molecules by real time monitoring during liposome tubulation, protein  
43  
44 structural analysis and detail TEM image analysis of tubulated liposomes would clarify the  
45  
46 importance of this interaction in liposome tubulation and in magnetosome formation of  
47  
48 magnetotactic bacteria.  
49

50  
51 In summary, the interaction of MamY protein and the partial amino acid sequences  
52  
53 of MamY with CL was demonstrated in this study. In addition, the supplementation of CL  
54  
55 into liposome revealed the enhancement of lipid tubulation efficiency by MamY protein.  
56  
57  
58  
59  
60

1  
2  
3  
4 The results in this manuscript not only give us the hint to effectively synthesize lipid  
5 tubule by prokaryotic protein but also might suggest the presence of unique protein-lipid  
6 interaction for magnetosome formation in magnetotactic bacteria. The liposome  
7 tubulation event, investigated in this study, was induced by the external stimuli of protein  
8 addition. This technique could be useful tool for elucidation of biological reactions  
9 onto/within membrane structures with different curvature. In addition, although the  
10 synthesis efficiency of lipid tubule is still low (approximately 20%), the synthesized  
11 materials with unique characteristics, such as biocompatibility, high dispersibility, and the  
12 potential of diameter tuning with a further molecular engineering technique, could be  
13 useful for various applications in nanobiotechnology.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Acknowledgement**

27  
28 This work was supported by JSPS KAKENHI (Grant Numbers: 16K14488, 16H02421 and  
29 15H04192). M.T. thanks for funds from Foundation for Promotion of Material Science and  
30 Technology (MST) of Japan and the Royal Society UK under the Newton International  
31 Fellowships follow on funding scheme. And this work was supported in part by the  
32 international collaboration research projects sponsored by the JSPS and the Royal Society.  
33  
34 We thank Prof. Naoki Mochizuki and Dr. Michitaka Masuda for kindly providing plasmid  
35 pGEX6p3-AmphiphysinBAR (aa1-239). This paper is dedicated to Prof. Stephen Baldwin  
36 who contributed greatly to the conceptualization and initial experiments of this study. He  
37 is greatly missed.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Conflict of interest**

49 The authors declare no financial or commercial conflict of interest.  
50  
51  
52  
53

### 54 **5 References**

- 1  
2  
3  
4 [1] B. Yang, S. Kamiya, K. Yoshida, T. Shimizu, *Chem. Commun. (Camb)*. **2004**, 500–501.  
5  
6 [2] Y. Zhou, M. Kogiso, C. He, Y. Shimizu, N. Koshizoki, T. Shimizu, *Adv. Mater.* **2007**, *19*,  
7  
8 1054–1058.  
9  
10 [3] I. Kim, Y. H. Park, D. A. Rey, C. A. Batt, *J. Drug Target.* **2008**, *16*, 716–722.  
11  
12 [4] S. Baral, P. Schoen, *Chem. Mater.* **1993**, *5*, 145–147.  
13  
14 [5] M. Tanaka, K. Critchley, T. Matsunaga, S. D. Evans, S. S. Staniland, *Small* **2012**, *8*,  
15  
16 1590–1595.  
17  
18 [6] A. J. Patil, E. Muthusamy, A. M. Seddon, S. Mann, *Adv. Mater.* **2003**, *15*, 1816–1819.  
19  
20 [7] T. Shimizu, in *J. Polym. Sci. Part A Polym. Chem.*, **2006**, pp. 5137–5152.  
21  
22 [8] Y. Zhou, *Crit. Rev. Solid State Mater. Sci.* **2008**, *33*, 183–196.  
23  
24 [9] N. Kameta, H. Minamikawa, M. Masuda, G. Mizuno, T. Shimizu, *Soft Matter* **2008**, *4*,  
25  
26 1681.  
27  
28 [10] J. M. Schnur, R. Price, A. S. Rudolph, *J. Control. Release* **1994**, *28*, 3–13.  
29  
30 [11] P. Yager, P. E. Schoen, *Mol. Cryst. Liq. Cryst.* **1984**, *106*, 371–381.  
31  
32 [12] J. P. Douliez, C. Gaillard, L. Navailles, F. Nallet, *Langmuir* **2006**, *22*, 2942–2945.  
33  
34 [13] S. Kamiya, H. Minamikawa, J. H. Jung, B. Yang, M. Masuda, T. Shimizu, *Langmuir*  
35  
36 **2005**, *21*, 743–750.  
37  
38 [14] M. Heinrich, A. Tian, C. Esposito, T. Baumgart, *Proc. Natl. Acad. Sci.* **2010**, *107*, 7208–  
39  
40 7213.  
41  
42 [15] H. Bi, D. Fu, L. Wang, X. Han, *ACS Nano* **2014**, *8*, 3961–3969.  
43  
44 [16] C. Pernpeintner, J. A. Frank, P. Urban, C. R. Roeske, S. D. Pitzl, D. Trauner, T.  
45  
46 Lohmüller, *Langmuir* **2017**, *33*, 4083–4089.  
47  
48 [17] Y. Yu, S. Granick, *J. Am. Chem. Soc.* **2009**, *131*, 14158–14159.  
49  
50 [18] M. Masuda, S. Takeda, M. Sone, T. Ohki, H. Mori, Y. Kamioka, N. Mochizuki, *EMBO J.*  
51  
52 **2006**, *25*, 2889–2897.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 [19] J. C. Stachowiak, C. C. Hayden, D. Y. Sasaki, *Proc. Natl. Acad. Sci.* **2010**, *107*, 7781–  
5 7786.  
6  
7  
8 [20] N. Gopaldass, B. Fauvet, H. Lashuel, A. Roux, A. Mayer, *EMBO J.* **2017**, e201796859.  
9  
10 [21] B. Tandler, C. L. Hoppel, J. A. Mears, *Antioxidants* **2018**, *7*, 30.  
11  
12 [22] W. J. Nicolas, M. S. Grison, E. M. Bayer, *J. Exp. Bot.* **2018**, *69*, 91–103.  
13  
14 [23] M. M. Kozlov, F. Campelo, N. Liska, L. V. Chernomordik, S. J. Marrink, H. T. McMahon,  
15 *Curr. Opin. Cell Biol.* **2014**, *29*, 53–60.  
16  
17 [24] M. J. Scholze, K. S. Barbieux, A. De Simone, *bioRxiv* **2017**, 215079.  
18  
19 [25] W. Zhao, L. Hanson, H. Y. Lou, M. Akamatsu, P. D. Chowdary, F. Santoro, J. R. Marks,  
20 A. Grassart, D. G. Drubin, Y. Cui, et al., *Nat. Nanotechnol.* **2017**, *12*, 750–756.  
21  
22 [26] T. Hirama, S. M. Lu, J. G. Kay, M. Maekawa, M. M. Kozlov, S. Grinstein, G. D. Fairn, *Nat.*  
23 *Commun.* **2017**, *8*, 1393.  
24  
25 [27] Y. F. Barooji, A. Rørvig-Lund, S. Semsey, S. N. S. Reihani, P. M. Bendix, *Sci. Rep.* **2016**,  
26 *6*, 30054.  
27  
28 [28] Y. Tanaka-Takiguchi, T. Itoh, K. Tsujita, S. Yamada, M. Yanagisawa, K. Fujiwara, A.  
29 Yamamoto, M. Ichikawa, K. Takiguchi, *Langmuir* **2013**, *29*, 328–336.  
30  
31 [29] G. Carranza, F. Angius, O. Ilioaia, A. Solgadi, B. Miroux, I. Arechaga, *Biochim. Biophys.*  
32 *Acta - Biomembr.* **2017**, *1859*, 1124–1132.  
33  
34 [30] T. Romantsov, K. Gonzalez, N. Sahtout, D. E. Culham, C. Coumoundouros, J. Garner, C.  
35 H. Kerr, L. Chang, R. J. Turner, J. M. Wood, *Mol. Microbiol.* **2018**, *107*, 623–638.  
36  
37 [31] P. C. Hsu, F. Samsudin, J. Shearer, S. Khalid, *J. Phys. Chem. Lett.* **2017**, *8*, 5513–5518.  
38  
39 [32] L. D. Renner, D. B. Weibel, *J. Biol. Chem.* **2012**, *287*, 38835–38844.  
40  
41 [33] L. D. Renner, D. B. Weibel, *Proc. Natl. Acad. Sci.* **2011**, *108*, 6264–6269.  
42  
43 [34] Y. A. Gorby, T. J. Beveridge, R. P. Blakemore, *J. Bacteriol.* **1988**, *170*, 834–841.  
44  
45 [35] R. Blakemore, *Science* **1975**, *190*, 377–9.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 [36] M. Tanaka, Y. Okamura, A. Arakaki, T. Tanaka, H. Takeyama, T. Matsunaga,  
5  
6 *Proteomics* **2006**, *6*, 5234–5247.  
7  
8 [37] T. Matsunaga, M. Nemoto, A. Arakaki, M. Tanaka, *Proteomics* **2009**, *9*, 3341–3352.  
9  
10 [38] K. Grünberg, E. Müller, A. Otto, R. Reszka, D. Linder, M. Kube, R. Reinhardt, Schüler  
11  
12 D., *Appl. Environ. Microbiol.* **2004**, *70*, 1040–1050.  
13  
14 [39] D. Murat, A. Quinlan, H. Vali, A. Komeili, *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*,  
15  
16 5593–5598.  
17  
18 [40] A. Lohße, S. Borg, O. Raschdorf, I. Kolinko, E. Tompa, M. Pósfai, D. Faivre, J.  
19  
20 Baumgartner, D. Schüler, *J. Bacteriol.* **2014**, *196*, 2658–2669.  
21  
22 [41] A. Komeili, Z. Li, D. K. Newman, G. J. Jensen, *Science* **2006**, *311*, 242–245.  
23  
24 [42] A. Scheffel, D. Schüler, *J. Bacteriol.* **2007**, *189*, 6437–6446.  
25  
26 [43] O. Draper, M. E. Byrne, Z. Li, S. Keyhani, J. C. Barrozo, G. Jensen, A. Komeili, *Mol.*  
27  
28 *Microbiol.* **2011**, *82*, 342–354.  
29  
30 [44] A. Arakaki, J. Webb, T. Matsunaga, *J. Biol. Chem.* **2003**, *278*, 8745–8750.  
31  
32 [45] A. Yamagishi, M. Tanaka, J. J. M. Lenders, J. Thiesbrummel, N. A. J. M. Sommerdijk, T.  
33  
34 Matsunaga, A. Arakaki, *Sci. Rep.* **2016**, *6*, 29785.  
35  
36 [46] A. Arakaki, A. Yamagishi, A. Fukuyo, M. Tanaka, T. Matsunaga, *Mol. Microbiol.* **2014**,  
37  
38 *93*, 554–567.  
39  
40 [47] M. Tanaka, A. Arakaki, T. Matsunaga, *Mol. Microbiol.* **2010**, *76*, 480–488.  
41  
42 [48] M. Tanaka, Y. Nakata, T. Mori, Y. Okamura, H. Miyasaka, H. Takeyama, T. Matsunaga,  
43  
44 *Appl. Environ. Microbiol.* **2008**, *74*, 3342–3348.  
45  
46 [49] M. Tanaka, S. Hikiba, K. Yamashita, M. Muto, M. Okochi, *Acta Biomater.* **2017**, *1*, 13–  
47  
48 26.  
49  
50 [50] M. Okochi, M. Muto, K. Yanai, M. Tanaka, T. Onodera, J. Wang, H. Ueda, K. Toko, *ACS*  
51  
52 *Comb. Sci.* **2017**, *19*, 625–632.  
53  
54 [51] E. G. Bligh, W. J. Dyer, *Can. J. Biochem. Physiol.* **1959**, *37*, 911–917.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 [52] K. Takei, V. I. Slepnev, V. Haucke, P. De Camilli, *Nat. Cell Biol.* **1999**, *1*, 33–39.  
5  
6 [53] L. A. Gish, J. M. Gagne, L. Han, B. J. DeYoung, S. E. Clark, *PLoS One* **2013**, *8*, DOI  
7  
8 10.1371/journal.pone.0066345.  
9  
10 [54] N. B. Ray, L. Durairaj, B. B. Chen, B. J. McVerry, A. J. Ryan, M. Donahoe, A. K.  
11  
12 Waltenbaugh, C. P. O'Donnell, F. C. Henderson, C. A. Etscheidt, et al., *Nat. Med.* **2010**,  
13  
14 *16*, 1120–1127.  
15  
16 [55] M. Desmurs, M. Foti, E. Raemy, F. M. Vaz, J.-C. Martinou, A. Bairoch, L. Lane, *Mol. Cell.*  
17  
18 *Biol.* **2015**, *35*, 1139–1156.  
19  
20 [56] K.-A. Nave, H. B. Werner, *Annu. Rev. Cell Dev. Biol.* **2014**, *30*, 503–533.  
21  
22 [57] Y. Kinjo, D. Wu, G. Kim, G. W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C. H.  
23  
24 Wong, M. Kronenberg, *Nature* **2005**, *434*, 520–525.  
25  
26 [58] D. Balkwill, J. K. Fredrickson, M. F. Romine, *Prokaryotes SE - 23* **2006**, 605–629.  
27  
28 [59] Y. Sheng, A. Sali, H. Herzog, J. Lahnstein, S. A. Krilis, *J Immunol* **1996**, *157*, 3744–  
29  
30 3751.  
31  
32 [60] A. Shimada, H. Niwa, K. Tsujita, S. Suetsugu, K. Nitta, K. Hanawa-Suetsugu, R.  
33  
34 Akasaka, Y. Nishino, M. Toyama, L. Chen, et al., *Cell* **2007**, *129*, 761–772.  
35  
36 [61] C. M. Khursigara, X. Wu, P. Zhang, J. Lefman, S. Subramaniam, *Proc. Natl. Acad. Sci. U.*  
37  
38 *S. A.* **2008**, *105*, 16555–16560.  
39  
40 [62] D. T. Jones, *J. Mol. Biol.* **1999**, *292*, 195–202.  
41  
42 [63] C. Katz, L. Levy-Beladev, S. Rotem-Bamberger, T. Rito, S. G. D. Rüdiger, A. Friedler,  
43  
44 *Chem. Soc. Rev.* **2011**, *40*, 2131–2145.  
45  
46 [64] T. Doan, J. Coleman, K. A. Marquis, A. J. Meeske, B. M. Burton, E. Karatekin, D. Z.  
47  
48 Rudner, *Genes Dev.* **2013**, *27*, 322–334.  
49  
50 [65] P. Bernal, J. Muñoz-Rojas, A. Hurtado, J. L. Ramos, A. Segura, *Environ. Microbiol.*  
51  
52 **2007**, *9*, 1135–1145.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 [66] R. D. Finn, P. Coggill, R. Y. Eberhardt, S. R. Eddy, J. Mistry, A. L. Mitchell, S. C. Potter,  
5 M. Punta, M. Qureshi, A. Sangrador-Vegas, et al., *Nucleic Acids Res.* **2016**, *44*, D279–  
6 D285.  
7  
8  
9  
10 [67] J. Dudek, *Front. Cell Dev. Biol.* **2017**, *5*, 90.  
11  
12 [68] A. Arakaki, D. Kikuchi, M. Tanaka, A. Yamagishi, T. Yoda, T. Matsunaga, *J. Bacteriol.*  
13 **2016**, JB.00280-16.  
14  
15  
16 [69] T. Matsunaga, Y. Okamura, Y. Fukuda, A. T. Wahyudi, Y. Murase, H. Takeyama, *DNA*  
17 *Res.* **2005**, *12*, 157–166.  
18  
19  
20 [70] T. Nishimura, N. Morone, S. Suetsugu, *Biochem. Soc. Trans.* **2018**, *46*, 379–389.  
21  
22 [71] M. Moniruzzaman, M. Z. Islam, S. Sharmin, H. Dohra, M. Yamazaki, *Biochemistry*  
23 **2017**, *56*, 4419–4431.  
24  
25  
26 [72] Y. Yamashita, S. M. Masum, T. Tanaka, M. Yamazaki, *Langmuir* **2002**, *18*, 9638–9641.  
27  
28 [73] T. Wollert, C. Wunder, J. Lippincott-Schwartz, J. H. Hurley, *Nature* **2009**, *458*, 172–  
29 177.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Evaluation of liposome tubulation activity in the presence of CL.

Magnetosome lipid : Cardiolipin	Tubulated/Observed	Efficiency (%)
100 : 0	6/183	3.3
97.5 : 2.5	13/175	7.4
95 : 5	41/203	20.2
90 : 10	38/224	17.0
80 : 20	33/179	18.4
100 : 0 (no protein)	0/168	0.0
90 : 10 (no protein)	0/170	0.0

**Table 2.** Characteristics of CL binding peptides obtained from MamY amino acid sequence.

Name	Peptide number	Sequence	Subtracted intensity <sup>a)</sup> (a.u. × 10 <sup>5</sup> )	pI <sup>b)</sup>	GRAVY <sup>c)</sup>	Charge <sup>d)</sup>	K <sub>d</sub> (μM) <sup>e)</sup>
p1	10	AAFGKLNSASRAALI	2.71±0.18	11.00	0.67	+2	4.75±0.78
p2	142	FISTLTTAYFAGDKN	2.34±0.42	5.83	0.13	0	11.97±5.22
p3	155	NRSEQLRRCAEDTES	2.08±0.26	4.87	-1.91	-1.1	1.62±0.61
p4	105	RVLSQEITQELSQIT	2.04±0.45	4.53	-0.28	-1	2.02±0.47
p5	163	RQQISKILREAREIR	1.94±0.27	11.54	-1.17	+3	1.19±0.19
p6	141	RKFISTLTTAYFAGD	1.92±0.22	8.59	0.07	+1	0.65±0.31
p7	104	SQRVLSQEITQELSQ	1.56±0.17	4.53	-0.82	-1	1.36±0.33
p8	26	GWKNLFTMLPHEFFI	1.55±0.14	6.75	0.31	+0.1	2.31±0.37
C	C	KNKEKK	0.45±0.11	10.0	-3.77	+3	9.49±3.58

a) The fluorescence intensity was shown from the intensity of CL containing DOPC liposome subtracted with DOPC liposome. b), c) and d) were analyzed using the ProtParam tool in ExPASy (<http://web.expasy.org/protparam/>). a) and e) Average values (±SD) are based on triplicate peptide spots.

## Figure legends

**Figure 1.** Dot-blot assay of MamY protein for the interactions with phospholipids.

Nitrocellulose-immobilized phospholipids at 100 pmol per spot were incubated with 0.5  $\mu\text{g ml}^{-1}$  of proteins (**A**; MamY-GST, **B**; AmphiphysinBAR-GST, and **C**; GST). Top image shows the lipid profiles in array. Binding of proteins was detected by anti-GST HRP conjugated antibody with chemiluminescent substrate.

**Figure 2.** Liposome tubulation assay with MamY protein. Representative electron micrographs of the magnetosome membrane extracted lipid liposome (ML) with CL supplementation (5%) (right) and without the supplementation (left) before (top) and after (middle) the MamY protein addition at 30  $\mu\text{M}$ . The bottom images were enlarged from the square region in middle images to show the lipid tubule structure. *The images are representative of several independent experiments. The tubulation efficiency was shown in Table 1.*

**Figure 3.** Evaluation of CL binding property in peptide library comprising partial

sequences in amino acid sequence of MamY protein by using the peptide array.


Designed peptide array (**A**) and the fluorescent images of peptide arrays after binding with (**B-1**) CL containing DOPC liposome and (**B-2**) only DOPC liposome. (**C**) Fluorescent intensity profile of each peptide spot; the intensity from CL containing DOPC liposome was subtracted from the intensity of only DOPC liposome. *Error bar indicates SD derived from triple results.*

1  
2  
3  
4 **Supplementary figure 1.** Blank-subtracted SPR sensorgrams of binding analysis from (A)  
5 AAFGKLNSASRAALI peptide-immobilized chip and (B) AAAA peptide-immobilized chip in  
6 case of flowing 10% CL-containing DOPC liposome and DOPC liposome. The contact time  
7 is 180 s. The higher response could be seen when CL-containing liposome was flowed over  
8 AAFGKLNSASRAALI peptide-immobilized chip.  
9  
10  
11  
12  
13

14  
15  
16 **Supplementary figure 2.** Evaluation of dissociation constant ( $K_d$ ) of 8 CL binding peptide  
17 candidates using peptide array. Synthesized peptide arrays were incubated in the solution  
18 containing DOPC with CL and without CL. (A) The top images show the peptide array after  
19 binding assay with different concentration of liposome. (B) In order to obtain the  $K_d$  value  
20 of candidate peptides to CL, subtracted fluorescence intensities were plotted from the  
21 different intensities between binding assays with CL-containing DOPC liposome and DOPC  
22 liposome. Error bar indicates standard deviation (SD) derived from triple results.  
23  
24  
25  
26  
27  
28  
29  
30


31  
32 **Supplementary figure 3.** Predicted secondary structure of MamY protein by PSIPRED  
33 with identified CL binding peptide regions. Screened peptides as CL binder were  
34 underlined.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Triglyceride	○	○	PtdIns
Diacylglycerol (DAG)	○	○	PtdIns(4)P
Phosphatidic Acid (PA)	○	○	PtdIns(4,5)P <sub>2</sub>
Phosphatidylserine (PS)	○	○	PtdIns(3,4,5)P <sub>3</sub>
Phosphatidylethanolamine (PE)	○	○	Cholesterol
Phosphatidylcholine (PC)	○	○	Sphingomyelin
Phosphatidylglycerol (PG)	○	○	Sulfatide
Cardiolipin (CL)	○	○	Solvent Blank




**Figure 1.** Dot-blot assay of MamY protein for the interactions with phospholipids.

Nitrocellulose-immobilized phospholipids at 100 pmol per spot were incubated with 0.5  $\mu\text{g ml}^{-1}$  of proteins (A; MamY-GST, B; AmphiphysinBAR-GST, and C; GST). Top image shows the lipid profiles in array. Binding of proteins was detected by anti-GST HRP conjugated antibody with chemiluminescent substrate.




**Figure 2.** Liposome tubulation assay with MamY protein. Representative electron micrographs of the magnetosome membrane extracted lipid liposome (ML) with CL supplementation (5%) (right) and without the supplementation (left) before (top) and after (middle) the MamY protein addition at 30  $\mu\text{M}$ . The bottom images were enlarged from the square region in middle images to show the lipid tubule structure.


### A. Schematic illustration of peptide array design from MamY protein amino acid sequence




### B-1. CL containing DOPC liposome



### B-2. DOPC liposome




### C. Quantitative evaluation of CL binding peptide using peptide array




**Figure 3.** Evaluation of CL binding property in peptide library comprising partial sequences in amino acid sequence of MamY protein by using the peptide array.

Designed peptide array (A) and the fluorescent images of peptide arrays after binding with (B-1) CL containing DOPC liposome and (B-2) only DOPC liposome. (C) Fluorescent intensity profile of each peptide spot; the intensity from CL containing DOPC liposome was subtracted from the intensity of only DOPC liposome. Error bar indicates SD derived from triple results.



**Supplementary figure 1.** Blank-subtracted SPR sensorgrams of binding analysis from (A) AAFGKLNSASRAALI peptide-immobilized chip and (B) AAAA peptide-immobilized chip in case of flowing 10% CL-containing DOPC liposome and DOPC liposome. The contact time is 180 s. The higher response could be seen when CL-containing liposome was flowed over AAFGKLNSASRAALI peptide-immobilized chip.



**Supplementary figure 2.** Evaluation of dissociation constant ( $K_d$ ) of 8 CL binding peptide candidates using peptide array. Synthesized peptide arrays were incubated in the solution containing DOPC with CL and without CL. (A) The top images show the peptide array after binding assay with different concentration of liposome. (B) In order to obtain the  $K_d$  value of candidate peptides to CL, subtracted fluorescence intensities were plotted from the different intensities between binding assays with CL-containing DOPC liposome and DOPC liposome. Error bar indicates standard deviation (SD) derived from triple results.

